ADJUVANTED INFLUENZA VACCINES INCLUDING CYTOKINE-INDUCING AGENTS
While oil-in-water emulsions are excellent adjuvants for influenza vaccines, their efficacy can be improved by additionally including other immunostimulating agent(s) to improve cytokine responses, such as γ-interferon response. Thus, a vaccine comprises (i) an influenza virus antigen; (ii) an oil-in-water emulsion adjuvant; and (iii) a cytokine-inducing agent.
1 . An immunogenic composition comprising: (i) an influenza virus antigen;
(ii) an oil-in-water emulsion adjuvant; and (iii) a cytokine-inducing agent.
2 . The composition of claim 1 , wherein the influenza virus antigen is inactivated virus.
3 . The composition of claim 1 , wherein the influenza virus antigen comprises whole virus, split virus, or purified surface antigens.
4 . The composition of claim 1 , wherein the influenza virus antigen is from a H1, H2, H3, H5, H7 or H9 influenza A virus subtype.
5 . The composition of claim 1 , wherein the influenza virus antigen is prepared from an influenza virus grown on eggs.
6 . The composition of claim 1 , wherein the influenza virus antigen is prepared from an influenza virus grown on cell culture.
7 . The composition of claim 1 , wherein the composition is free from ovalbumin, ovomucoid and chicken DNA.
8 . The composition of claim 6 , wherein the composition contains less than 10 ng of cellular DNA from the cell culture host.
9 . The composition of claim 6 , wherein the composition contains less than 10 ng of DNA that is 100 nucleotides or longer.
10 . The composition of claim 1 , wherein the influenza virus antigen is prepared from an influenza virus having one or more RNA segments from an A/PR/8/34 influenza virus.
11 . The composition of claim 1 , wherein the influenza virus antigen is prepared from an influenza virus obtained by reverse genetics techniques.
12 . The composition of claim 6 , wherein the cell culture is a microcarrier culture, an adherent culture, or a suspension culture.
13 . The composition of claim 6 , wherein the cell culture is serum-free.
14 . The composition of claim 1 , wherein the influenza virus antigen is prepared from an influenza virus grown on MDCK cells.
15 . The composition of claim 1 , wherein the composition contains between 0.1 and 20 μg of haemagglutinin per viral strain.
16 . The composition of claim 1 , wherein the oil(s) and surfactant(s) in the emulsion are biodegradable and biocompatible.
17 . The composition of claim 1 , wherein the emulsion has droplets with a sub-micron diameter.
18 . The composition of claim 1 , wherein the emulsion includes a terpenoid.
19 . The composition of claim 1 , wherein the emulsion includes squalene.
20 . The composition of claim 1 , wherein the emulsion includes a tocopherol.
21 . The composition of claim 20 , wherein the tocopherol is DL-[alpha]-tocopherol.
22 . The composition of claim 1 , wherein the emulsion includes a polyoxyethylene sorbitan esters surfactant, a octoxynol surfactant, and/or a sorbitan ester.
23 . The composition of claim 1 , wherein the cytokine-inducing agent elicits the release of interferon-γ.
24 . The composition of claim 1 , wherein the cytokine-inducing agent is an agonist of one or more of the human TLR1, TLR2, TLR3, TLR4, TLR7, TLR8, and/or TLR9.
25 . The composition of claim 1 , wherein the cytokine-inducing agent is selected from: an immunostimulatory oligonucleotide; a 3-O-deacylated monophosphoryl lipid A (3dMPL); an imidazoquinoline compound; and/or an aminoalkyl glucosaminide phosphate derivative.
26 . The composition of claim 25 , wherein the cytokine-inducing agent is 3dMPL, and where at least 10% by weight of the 3dMPL is the hexaacyl chain fonn.
27 . The composition of claim 25 , wherein the cytokine-inducing agent is 3dMPL, and where the 3dMPL is in the form of particles with a diameter <150 nm.
28 . The composition of claim 25 , wherein the cytokine-inducing agent is 3dMPL, and where the 3dMPL is located in the aqueous phase of the emulsion.
29 . The composition of claim 1 , being substantially free from mercurial material.
30 . The composition of claim 1 , including between 1 and 20 mg/ml sodium chloride.
31 . The composition of claim 1 , having an osmolality between 200 and 400 m[theta]sm/kg.
32 . The composition of claim 1 , including one or more buffer(s).
33 . The composition of claim 32 , wherein the buffer(s) include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer; or a citrate buffer.
34 . The composition of claim 1 , having a pH between 5.0 and 8.1.
35 . The composition of claim 1 , containing <1 endotoxin unit per dose.
36 . The composition of claim 1 , being gluten free.
37 . The composition of claim 1 , wherein the composition includes two influenza A strains and one influenza B strain.
38 . The composition of claim 1 , wherein the composition is a monovalent vaccine against a pandemic influenza virus strain.
39 . A method for preparing an immunogenic composition comprising the steps of combining: (i) an influenza virus antigen; (ii) an oil-in-water emulsion adjuvant; and (iii) a cytokine inducing agent.
40 . A kit comprising: (i) a first kit component comprising an influenza virus antigen; and (ii) a second kit component comprising an oil-in-water emulsion adjuvant, wherein either (a) the first component or the second component includes a cytokine inducing agent, or (b) the kit includes a third kit component comprising a cytokine inducing agent.
41 . The kit of claim 40 , wherein the first component and the second component are in separate containers.
42 . The kit of claim 41 , wherein the first and second components are in vials.
43 . The kit of claim 41 , wherein one of the first and second components is in a syringe, and wherein the other component is in a vial.
44 . The kit of claim 42 , wherein the vial is made of a glass or plastic material.
45 . The kit of claim 42 , wherein the vial is sealed with a latex-free stopper.
46 . A method of raising an immune response in a patient, comprising the step of administering to the patient a medicament, wherein the medicament is a composition of claim 1 .
47 . (canceled)
48 . The method of claim 46 , wherein the medicament is administered to a patient at substantially the same time as a pneumococcal conjugate vaccine.
49 . The method of claim 46 , wherein the medicament is administered to a patient at substantially the same time as a an antiviral compound active against influenza virus.